Adaptive and Sequenta combine to bring immunosequencing to the fore
This article was originally published in Clinica
Executive Summary
Two privately-held companies specializing in immunosequencing, which uses next-generation sequencing tools to allow targeted and in-depth analysis of our unique adaptive immune system, are combining to build critical mass and speed the adoption of this technology.